Standard Follow-up Program (SFP) for Breast Cancer Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Study summary
Motive:
In order to improve the treatment technique, a comprehensive follow-up program is needed to obtain all relevant patient, treatment and toxicity data from breast cancer patients.
Goal:to set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life.
A standard database of patiënts receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.
To set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life.
A standard database of patients receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.
Eligibility
Primary outcome measure(s)
- Score of Acute toxicity — Before start of radiation therapy and during radiation therapy and at 2 weeks after last day of radiation therapy.
Acute Toxicity is measured with Common Terminology Criteria for Adverse Events (CTCAE). - Score of Late toxicity — At one and two years after last day of radiation therapy.
Late Toxicity is measured with Common Terminology Criteria for Adverse Events (CTCAE).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University Medical Center Groningen | Groningen | Netherlands |
More University Medical Center Groningen trials in the Netherlands
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06429995 on ClinicalTrials.gov ↗ ← All trials in the Netherlands